Abstract
Low natural killer (NK) cell activity against the K-562 leukemia cell line was observed in patients with acute leukemia in the early stages of remission, i.e., 2–4 months (11.3%±7.95% specific target cell lysis). This parameter was found to be normal among leukemia patients after a longer time in remission (19.53%±7.55%) when compared with healthy donors (18.46%±12.98%). A similar pattern of activity was observed in studies of antibody-dependent cell-mediated cytolysis (ADCC) to the CEM lymphoid tumor cell line in the same group (37.58%±12.4% vs. 51%±6.79% specific target cell lysis).
ADCC to chicken red blood cells (CRBC) and to human red blood cells (HRBC) was not significantly different from that for healthy controls at either duration of remission.
Nine patients relapsed over a follow-up period of 9 months. They were found to have slightly lower NK activity (14.4%±9.3%) and ADCC to CEM (41.4%±8.5%) than the patients who remained in remission (17.1%±6.8%; 48.7%±9.7%, respectively).
These data indicate a lymphocyte deficit which may persist for some time after remission has been induced, and which may be due to the effect of leukemic cell burden or the effect of aggressive chemotherapy.
Keywords: Natural Killer, Natural Killer Cell, Acute Leukemia, Natural Killer Cell Activity, Natural Killer Activity
References
- 1.Bekesi JG, Holland JF. Modern trends in human leukemia, vol III. New York: Springer; 1979. Impact of specific immunotherapy in acute myelocytic leukemia; p. 79. [DOI] [PubMed] [Google Scholar]
- 2.Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res. 1978;23:305. doi: 10.1016/s0065-230x(08)60936-7. [DOI] [PubMed] [Google Scholar]
- 3.Hersh EM, Whitecar JP, McCredie KB. Chemotherapy immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med. 1971;285:1211. doi: 10.1056/NEJM197111252852201. [DOI] [PubMed] [Google Scholar]
- 4.Hersh EM, Gutterman JU, Mavligit GM, McCredie KB, Burgess M, Matthews A, Freireich EJ. Several studies of immunocompetence of patients undergoing chemotherapy for acute leukemia. J Clin Invest. 1974;54:401. doi: 10.1172/JCI107775. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Holm G. Lysis of antibody-treated human erythrocytes by human leucocytes and macrophages in tissue culture. Int Arch Allergy Appl Immunol. 1972;43:671. doi: 10.1159/000230883. [DOI] [PubMed] [Google Scholar]
- 6.Jondal M, Pross H. Surface markers on human B and T lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulation. Int J Cancer. 1975;15:596. doi: 10.1002/ijc.2910150409. [DOI] [PubMed] [Google Scholar]
- 7.Keating MJ, Smith TL, Gehan EA. Factors related to the length of complete remission in adult acute leukemia. Cancer. 1980;45:2017. doi: 10.1002/1097-0142(19800415)45:8<2017::aid-cncr2820450806>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
- 8.Kragballe K, Ellegaard J. Antibody-dependent monocyte mediated cytotoxicity. Serial studies in acute myeloid leukemia. Scand J Haematol. 1980;21:181. [PubMed] [Google Scholar]
- 9.Lotzova E, McCredie KB. Natural killer cells in mice and men and their possible biological significance. Cancer Immunol Immunother. 1978;4:215. [Google Scholar]
- 10.Lotzova E, McCredie KB, Maroun JA, Dicke KA, Freireich EJ. Some studies of natural killer cells in man. Transplant Proc. 1979;11:1390. [PubMed] [Google Scholar]
- 11.Lovchik JC, Hong R. Antibody-dependent cell-mediated cytolysis (ADCC). Analysis and projection. Prog Allergy. 1977;22:1. [PubMed] [Google Scholar]
- 12.Mavligit GM, Gutterman JU, McBride CM, Hersh EM. Multifaceted evaluation of tumor immunity using a salt-extracted colon carcinoma antigen. Proc Soc Exp Biol Med. 1972;140:1240. doi: 10.3181/00379727-140-36650. [DOI] [PubMed] [Google Scholar]
- 13.Morris DL, Hersh EM, Hsi BP, Gutterman JU, Marshall MM, Mavligit GM. Recall antigen-delayed type hypersensitivity skin testing in melanoma and acute leukemia patients and their associates. Cancer Res. 1979;39:219. [PubMed] [Google Scholar]
- 14.Nelson DL, Bundy BM, Pitchon HE, Blaese RM, Strober W. The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol. 1976;117:1472. [PubMed] [Google Scholar]
- 15.Poplack DG, Bonnard GD, Holiman BJ, Blaese RM. Monocyte-mediated antibody-dependent cellular cytotoxicity: A clinical test of monocyte function. Blood. 1976;48:809. [PubMed] [Google Scholar]
- 16.Shaw GM, Levy PC, Lobuglio AF. Human monocyte cytotoxicity to tumor cells. Antibody-dependent cytotoxicity. J Immunol. 1978;121:573. [PubMed] [Google Scholar]
- 17.Shaw GM, Levy PC, Lobuglio AF. Human lymphocyte, monocyte and neutrophil antibody-dependent cell-mediated cytotoxicity towards human erythrocytes. Cell Immunol. 1978;41:122. doi: 10.1016/s0008-8749(78)80032-x. [DOI] [PubMed] [Google Scholar]
- 18.Snedecor GW, Cochran WG. Statistical methods. Ames: Iowa State University Press; 1967. p. 128. [Google Scholar]
- 19.Takasugi M, Ramseyer A, Takasugi J. Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res. 1977;37:413. [PubMed] [Google Scholar]
- 20.Van VH, Fiere D, Doillon M, Martin C, Coittier B, Revol L. Delayed hypersensitivity skin reaction in the induction phase of remissioin in acute nonlymphoid leukemias. Biomedicine. 1978;28:166. [PubMed] [Google Scholar]
- 21.Vose BM, Vansky F, Argov S, Klein E. Natural cytotoxicity in man: Activity of lymph node and tumor infiltrating lymphocytes. Eur J Immunol. 1977;7:753. doi: 10.1002/eji.1830071102. [DOI] [PubMed] [Google Scholar]
- 22.Zighelboim J. Deficiency of antibody-dependent cellular cytotoxicity and mitogen-induced cellular cytotoxicity. Effector cell function in patients with acute myelogenous leukemia in remissioin. Cancer Res. 1979;39:3357. [PubMed] [Google Scholar]